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Background: The aim of this study was to identify critical gene pathways that are associated with lung cancer
metastasis to the brain.
Methods: The RNA-Seq approach was used to establish the expression profiles of a primary lung cancer, adjacent
benign tissue, and metastatic brain tumor from a single patient. The expression profiles of these three types of
tissues were compared to define differentially expressed genes, followed by serial-cluster analysis, gene ontology
analysis, pathway analysis, and knowledge-driven network analysis. Reverse transcription–polymerase chain reaction
(RT-PCR) was used to validate the expression of essential candidate genes in tissues from ten additional patients.
Results: Differential gene expression among these three types of tissues was classified into multiple clusters
according to the patterns of their alterations. Further bioinformatic analysis of these expression profile data showed
that the network of the signal transduction pathways related to actin cytoskeleton reorganization, cell migration,
and adhesion was associated with lung cancer metastasis to the brain. The expression of ACTN4 (actinin, alpha 4), a
cytoskeleton protein gene essential for cytoskeleton organization and cell motility, was significantly elevated in the
metastatic brain tumor but not in the primary lung cancer tissue.
Conclusions: The signaling pathways involved in the regulation of cytoskeleton reorganization, cell motility, and
focal adhesion play a role in the process of lung cancer metastasis to the brain. The contribution of ACTN4 to the
process of lung cancer metastasis to the brain could be mainly through regulation of actin cytoskeleton reorganization,
cell motility, and focal adhesion.
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Metastatic brain tumors are the most common type of
brain tumor in adults and are associated with a poor
survival of patients (median survival time = 3–6 months)
[1]. A total of 40–50% of brain metastases originate from
lung cancer [2]. Studies of differential gene expression
between brain metastases and primary lung cancer have
suggested that many genes may be involved in the brain* Correspondence: jy7555@163.com; shi123jingwei@163.com
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proach, more than 200 genes, including genes encoding
plasma membrane proteins, antigen proteins, and cyto-
skeletal proteins, have been found to be differentially
expressed between a metastatic brain tumor and a lung
adenocarcinoma [3]. These genes function in cell inter-
action, attachment, and motility.
Actinin, alpha 4 (ACTN4), a nonmuscle cytoskeleton
protein, has been frequently reported to be associated
with cell motility and cancer metastasis. Honda et al.
have suggested that cytoplasmic ACTN4 increases cell
motility and is associated with a high metastatic poten-
tial and a poor prognosis of cancer based on their stud-
ies on multiple cancer cell lines, including lung canceris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4]. Since then, ACTN4 has been reported to be associ-
ated with the progression and metastasis of many types
of cancer, including breast [5], colorectal [6], pancreatic
[7], lung [8-10], brain [11], bladder [12,13], and ovarian
cancers [14-16] and salivary gland carcinoma [17]. In
addition, ACTN4 was found to be highly expressed in a
poor survival group of patients with non-small cell lung
cancer, suggesting that ACTN4 is a significant prognostic
predictor in this cohort of patients [8]. A novel alterna-
tive splice variant RNA of ACTN4 has been suggested to
be a candidate diagnostic marker of human small cell
lung cancer [9] and a prognostic factor for patients with
high-grade neuroendocrine pulmonary tumors [10].
However, in contrast to the aforementioned function of
ACTN4 as a positive regulator of tumorigenesis or cancer
metastasis, several studies have suggested that ACTN4
may function like a tumor suppressor to suppress malig-
nant behaviors of cancer cells [18,19]. Therefore, the asso-
ciation of ACTN4 expression with tumorigenicity and
cancer metastasis needs to be further investigated in the
clinic.
In order to define the critical signaling pathways and
genes that contribute to the brain metastasis of lung
cancer, we used the RNA-Seq approach to investigate
the expression profiles of three types of tissues (primary
lung cancer, adjacent benign lung tissue, and metastatic
brain tissue) from one patient. Subsequently, a series of
bioinformatic analyses were performed with the RNA-
Seq data to identify differentially expressed genes among
these three types of tissues and to discover the critical




A 47-year-old female patient was found to have a space-
occupying lesion in her lung in January 2009. A diagno-
sis of poorly/moderately differentiated adenocarcinoma
with a primary tumor–lymph node–distant metastasis
stage of T2N1Mx in the right middle lobe of the lung
was made in January 2010. Resection of the lower part
of the right middle lobe was conducted and followed by
chemotherapy. The metastatic tumor at the right frontal
lobe of the brain was found and resected in December
2010. Pathological analyses showed that the tumor was a
poorly/moderately differentiated adenocarcinoma that
had metastasized from the lung. The adjacent benign
lung tissue (N16), the original lung cancer (T16), and
the metastatic brain tumor (T30) were collected. This
study was approved by the institutional review board of
China-Japan Union Hospital of Jilin University and con-
ducted in accordance with the ethical guidelines of the
Declaration of Helsinki. The patient had signed a consentform before the study. In addition, we collected lung can-
cer and para-tumor tissues from ten patients for the con-
firmation study.RNA isolation and RNA-seq library preparation
Total RNA was isolated from the tissues using a Trizol re-
agent (Invitrogen, Carlsbad, CA, USA). The RNA quality
was assessed using a Bioanalyzer 2200 (Agilent, Santa
Clara, CA, USA), and the samples were stored at −80°C
until use. The RNA integrity numbers (RIN) of these RNA
samples were more than 8.0 and were appropriate for
cDNA library construction.cDNA library construction and sequencing
The TruSeqTM RNA Sample Preparation Kit (Illumina,
Inc.) was used to construct the cDNA libraries for these
RNA samples, according to the manufacturer’s instruc-
tions. Briefly, oligo(dT) magnetic beads were applied to
purify mRNA using 10 μg of total RNA, and the purified
mRNA was subsequently fragmented into sizes of 200–
500 bp using divalent cations at 94°C for 5 min. Reverse
transcription (RT) of the first-strand cDNA from the
RNA fragments was performed using SuperScript II re-
verse transcriptase and random primers. The second
strand cDNA synthesis was performed using DNA poly-
merase I and RNase H. The synthesized cDNA frag-
ments were then end-repaired by adding a single “A”
base ligated with indexed adapters. These end-repaired
cDNA fragments were purified and enriched by the
polymerase chain reaction (PCR). The final cDNA librar-
ies were generated by size selection through 2% agarose
gel electrophoresis and quantified by a Bioanalyzer 2200.
The tagged cDNA libraries were pooled in an equal ratio
and loaded in a single lane of the Illumina HiSeqTM
2000 for paired-end sequencing.qRT-PCR
The endogenous control β-actin was used as a control for
RT-PCR amplification measurement of ACTN4 expression.
RT-PCR primers were β-actin (5′-CTGGAACGGTGAAG
GTGACA-3′ and 5′-AAGGGACTTCCTGTAACAATGC
A-3′) and ACTN4 (5′-ACAAGCCCAACCTGGAC-3′ and
5′-GGTGCGGGCAATGGTG-3′). The cDNA was gener-
ated using a High-Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Foster City, CA, USA) and oli-
go(dT) primers, according to the manufacturer’s instruc-
tions. qPCR amplification was performed with the
following conditions: 2 min at 50°C, 10 min at 95°C, and
50 cycles of 15 s at 95°C, and 1 min at 60°C. The condi-
tions for the melting curve analysis were 1 min at 90°C,
30 s at 55°C, and 30 s at 95°C.
Table 1 Read numbers and mapping rates for the data
from these three types of tissues
Term N16 T16 T30
All reads 43279252 47347620 39090277
Mapped reads 32733724 43537602 39090265
Unique mapped reads 30080568 42382073 37298341
Repeat mapped reads 2653166 1155540 1791935
Mapping rates 0.756337563 0.91953095 0.911085382
Unique mapping rates 0.695034378 0.895125732 0.869320616
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The DEGseq algorithm was applied to filter the differen-
tially expressed genes with a fold change > 2, P < 0.5, and
false discovery rate (FDR) < 0.05 [20]. Gene ontology
(GO) analysis was performed according to the GO anno-
tations from NCBI (http://www.ncbi.nlm.nih.gov/), Uni-
Prot (http://www.uniprot.org/), and Gene Ontology
(http://www.geneontology.org/). The pathway analyses
were performed to determine the significant pathways
associated with the differentially expressed genes accord-
ing to the KEGG database. Fisher’s exact test, P values,
and FDRs were applied in the GO and pathway analyses,
according to a previous study [21]. Series cluster analysis
was performed to classify the differentially expressed
genes in eight clusters based on the reads per kb per
million reads (RPKM) change tendency of genes in these
three types of tissues (N16, T16, and T30), according to
a previous study [22]. For example, the genes with the
following expression pattern were classified into Cluster 1:
expression in N16 > expression in T16 = expression in
T30. The Path-Act-Network analyses were performed to
reveal the interactive network among the pathways with
enriched differentially expressed genes based on the
KEGG database, including the metabolism, membrane
transport, signal transduction, and cell cycle pathways
[23]. Cytoscape software was used to generate the graph-
ical representations of the pathways [24]. Gene-Act-Net
analyses were conducted to reveal the network of the dif-
ferentially expressed genes based on the interactions




Quality control was confirmed using Fast-QC to ensure
that the quality scores of the majority of the sequence
data were higher than 28 (data not shown), indicating
that the data quality was satisfactory for the following
analyses. Per sequence GC content curves also showed
that the GC distribution from our data matched with
the theoretical distribution (data not shown). A total of
32.7 × 106, 43.5 × 106, and 39.1 × 106 reads were obtained
for the adjacent benign, primary lung cancer, and meta-
static brain tumor tissues, respectively. In addition, the
mapping rates were 75.6%, 92.0%, and 91.1% for these
three types of tissues, respectively (Table 1).
Differentially expressed genes among these three types
of tissues
The RNA-Seq data from these three types of tissues that
had passed the aforementioned quality control were
mapped to the reference genome, followed by the statis-
tical analyses and expression analyses based on the RPKM
values and upper-quartile normalization (Additional file 1:Table S1), according to a previous study [25]. Subse-
quently, differentially expressed genes were further ana-
lyzed using the DEGSeq method. We found that there
were more than 900 differentially expressed genes between
N16 and T16 (Additional file 2: Table S2) and more than
800 differentially expressed genes between N16 and T30
(Additional file 3: Table S3). Notably, the expression of
ACTN4 did not show a significant difference between N16
and T16, but it was significantly increased in T30 (P =
2.26 × 10−17, FDR = 6.53 × 10−15).Series-cluster analysis
The series-cluster analysis of these differentially expressed
genes classified these genes into eight clusters based on the
trend of gene expression among the three types of tissues,
i.e., 15 genes in cluster 0 with RPKM N16 > RPKM T16 >
RPKM T30, 734 genes in cluster 1 with RPKMN16 >
RPKMT16 = RPKMT30, 157 genes in cluster 2 with RPKM
N16 > RPKM T16 < RPKM T30, no gene in cluster 3 with
RPKMN16 = RPKM T16 > RPKM T30; 294 genes in clus-
ter 4 with RPKM N16 = RPKM T16 < RPKM T30, 4 genes
in cluster 5 with RPKMN16 < RPKM T16 > RPKM T30, 5
genes in cluster 6 with RPKM N16 < RPKM T16 =
RPKMT30, and 3 genes in cluster 7 with RPKM N16 <
RPKM T16 < RPKM T30 (Figure 1). Among them, clusters
1, 4, and 2 were the largest clusters. For example, cluster 1
contained 734 genes, the expression levels of which were
significantly reduced in the primary lung cancer tissue
compared to that of the benign tissue but was comparable
between the primary lung cancer and the brain metastatic
tissues. The trend of altered expression among these three
types of tissues indicated that these genes possibly play a
role in the development of primary lung cancer but may
not be critical for brain metastasis. The genes in cluster 4
showed comparable levels of expression in primary lung
cancer and the adjacent benign tissues, but they were sig-
nificantly increased in the metastatic brain tumor. There-
fore, these genes are the most likely candidate genes to
play an important role in lung cancer metastasis to the
brain but may not be critical for lung cancer development.
ACTN4 was included in cluster 4 due to its significant in-
crease in the brain tumor tissue but no apparent increase
Figure 1 Eight clusters of genes with unique patterns of expression alteration in three types of tissues. Clusters were ordered based on the number of
genes assigned. The cluster number is shown at the top left corner of each cluster square. The number of genes grouped in each cluster is shown at
the bottom left corner of each cluster square. The distances from the left-end point, the middle point, and the right-end point of the polyline within
each cluster square to the bottom line of each square represent the relative (unscaled) gene expression levels among N16, T16, and T30, respectively.
For example, the expression levels of genes in cluster 1 were comparable between T16 and T30, but were lower in T16 than in N16.
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tissue.
Gene Ontology (GO) analysis
In order to explore the gene function relevant to the
brain metastasis of lung cancer, GO analysis was conducted
to group these differentially expressed genes into signaling
pathways. In brief, GO analysis of genes in cluster 4 showed
that these genes function in cytoskeleton-dependent
intracellular transport, calcium ion transportation, cel-
lular response to erythropoietin, EGFR signal regula-
tion, membrane-to-membrane docking, actin filament
bundle assembly, cell-cell adhesion, and actin cytoskel-
eton organization (Figure 2). Cluster 1 was shown to
regulate the reactive oxygen species metabolic process,
phagocytosis recognition, response to interlukin-6,
positive regulation of Rab GTPase activity, and positive
regulation of activation of JAK2 kinase activity and the
JAK-STAT cascade (Figure 2).
Pathway analysis
Further pathway analysis showed that the signaling path-
ways involved in antigen processing and presentation,
extracellular matrix (ECM)-receptor interaction, focal
adhesion, adherens junction, glycolysis and gluconeogen-
esis, regulation of actin cytoskeleton, and small cell lung
cancer, etc. are significantly enriched for the genes in
cluster 4 (Figure 3). In contrast, the signaling pathways
involved in aminoacyl-tRNA biosynthesis, apoptosis, and
hematopoietic cell lineage were enriched for the genes in
cluster 1 (Figure 3).
Pathway-Act-Network analysis
The interactive network among these enriched pathways
was subsequently explored. The inferred interactive
pathway network indicated that the signaling pathwaysinvolved in regulation of actin cytoskeleton, focal adhe-
sion, and adherens junction received stimulation from
the signaling pathways related to small cell lung cancer
through an ECM-receptor interaction and to auto-
immune thyroid disease through cell adhesion molecules
(CAMs) (Figure 4). The signaling pathway cascade was
revealed by this network. The signaling pathway involved
in regulation of actin cytoskeleton appears to be the pivotal
point of the Pathway-Act-Network.
Gene-Act-Network analysis
The Gene-Act-Network was established for the key genes
and was suggested to be the significant genes by GO ana-
lysis. The network data for the genes in clusters 1, 2, and 4
are shown in Figure 5. ACTN4, as one of the genes in clus-
ter 4, also is presented in the Gene-Act-Network.
qRT-PCR validation for ACTN4 expression in these three
types of tissues
Given the significant alteration of ACTN4 expression as
indicated by the above data, the expression levels of
ACTN4 in the three types of tissues were validated using
qRT-PCR. The data confirmed the RNA-Seq results and
showed the significantly increased expression of ACTN4
in the brain tumor tissues but comparable levels be-
tween primary lung cancer and the adjacent benign lung
tissues of 10 cases of independent samples (Figure 6).
Discussion
The expression profiles of primary lung cancer, adjacent
benign lung tissues, and brain metastatic tumor tissues
from a single patient were explored using the RNA-Seq
technique. A series of bioinformatic analyses revealed
gene functions and signaling pathways essential for lung
cancer development and brain metastasis. Among these
significant genes and pathways, ACTN4, encoding a
Figure 2 GO analysis for genes in cluster 4 (left) and cluster 1 (right).
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involved in regulation of actin cytoskeleton appeared to
play a pivotal role in the process of lung cancer metastasis
to the brain.Overall, the quality of the RNA-Seq data and read
mapping in our current study met the requirements for
the bioinformatic analyses. However, the total reads and
the mapping rate for the adjacent benign tissue were not
Figure 3 Pathway analysis for genes in cluster 4 (left) and cluster 1 (right).
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metastatic brain tumor tissues, probably resulting from
the limited amount of the benign tissue and the total
RNA available for the RNA-Seq approach. Nevertheless,
appropriate bioinformatic analyses were performed on
the RNA-Seq data from this study.
Differential gene expression analysis based on the
RPKM values with upper-quartile normalization revealed
that many genes were differentially expressed among
these three types of tissues. The RPKM values refer to
the reads per kb per million reads, according to a previ-
ous study [25]. These differentially expressed genes wereFigure 4 Pathway-Act-Network analysis.classified into eight clusters according to their changed
expression patterns in these three types of tissues. The
genes in cluster 4 are likely candidate genes that are in-
dispensable for lung cancer metastasis to the brain be-
cause these genes presented a significantly increased
expression in the metastatic brain tumors but not in the
primary lung cancer tissue or the benign tissue. The
genes in cluster 4 involve a variety of cellular functions,
including cytoskeleton-dependent intracellular transport,
membrane-to-membrane docking, actin filament bundle
assembly, cell-cell adhesion, and actin cytoskeleton
organization. The pathway analysis showed similar
Figure 5 Gene-Act-Network analysis. Genes in red belong to cluster 1, genes in green belong to cluster 2, and genes in pink belong to cluster 4.
Figure 6 qRT-PCR validation of ACTN4 expression in primary lung cancer, benign, and metastatic brain tissues. The expression level of ACTN4 is
higher in metastatic brain tissues than in primary lung cancer and benign tissues.
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volved in the signaling pathways associated with extracel-
lular molecular interaction, cellular adhesion, adherens
junction, and cytoskeleton organization. Interestingly,
ACTN4, encoding the alpha-actinin-4 protein, is among
cluster 4 genes. Alteration of ACTN4 expression was fur-
ther validated in these three types of tissues. ACTN4 has
been shown to play important roles in cytoskeleton
organization, cell adhesion, and cell migration. It has been
suggested that ACTN4 is indispensable for mononuclear
phagocyte response both in inflammation and tumor inva-
sion processes [26]. A recent study also supported that
ACTN4, particularly relying on its C-terminal tail, medi-
ates the cytoskeleton to the adhesion site during cell mi-
gration [27]. Our results demonstrated that these
functions of ACTN4 contribute to the process of lung
cancer metastasis to the brain.
Of note, another alpha-actinin gene, ACTN1, also ap-
peared in cluster 4 and presented a similar altered ex-
pression pattern as ACTN4 in these three types of
tissues. Indeed, ACTN1 has been reported to be essential
for cytoskeleton organization and cell motility in some
types of cells [28]. Foley and Young recently have shown
that ACTN4 and ACTN1 form a heterodimer in many
types of cells [29]. However, it also has been shown that
ACTN1 and ACTN4 contribute to distinct malignant
properties of astrocytoma cells and that ACTN4 may be
more important for cell motility and cell adhesion in
some cell lines [11].
In contrast to the functions of the genes in cluster 4,
the genes in cluster 1 presented distinct functions such
as regulation of reactive oxygen species, response to
interlukin-6, and regulation of the activation of JAK2
kinase activity. Accordingly, the pathway analysis results
were also distinct for the genes in cluster 1 and cluster
4. These results support our hypothesis that the genes in
cluster 1 likely include candidate genes critical for tumori-
genicity and that the genes in cluster 4 likely include can-
didate genes indispensable for metastasis.
The Pathway-Act-Network analysis based on the
RNA-Seq data from the three types of tissues suggested
that the pathways associated with the regulation of actin
cytoskeleton are the pivotal players during lung cancer
metastasis to the brain. Our data indicated that alter-
ation of these actin cytoskeleton pathways could contrib-
ute to lung cancer metastasis to the brain through
interacting with several other pathways involved in cellu-
lar processes, such as focal adhesion, adherens junction,
and ECM-receptor interaction. The important function
of the cytoskeleton in cancer metastasis has been widely
recognized [30]. The results from a study of transen-
dothelial migration of small cell lung cancer cells across
human brain microvascular endothelial cells showed that
the Rho/ROCK pathway contributes to actin cytoskeletonreorganization [31]. Consistent with this report, ras homo-
log family member C (RHOC) also appeared among the
genes in cluster 4, and its expression was increased in the
brain metastatic tumor but not in the primary lung cancer
tissue. ACTN4 is a critical gene related to actin cytoskel-
eton regulation and has been reported by multiple studies
to play an important role in cell adhesion, cell motility,
and cancer metastasis [4,5,12,15,17,18]. It also has been
suggested that ACTN4may interact with Rho family mem-
bers to regulate cell motility and cancer metastasis
through regulating cytoskeleton organization and focal
adhesion [11,27,28,30,31]. In short, the bioinformatic
analysis data revealed that the pathways involved with
actin cytoskeleton regulation were pivotal pathways in
the Pathway-Act-Network and that the ACTN4 gene
was one of the key players in the Gene-Act-Network.
Our current data are consistent with many previous
studies, including a microarray and immunostaining
data on ACTN4 and its association with pathways con-
tributing to lung cancer metastasis [8,10]. Our study
provided the first RNA-Seq data to support the essen-
tial function of the ACTN4 gene and the relevant cyto-
skeleton organization pathways in the brain metastasis
of lung carcinoma. However, the fact that only one pa-
tient’s samples were used is a major limitation of our
current study. A future study with more samples will
help to confirm and support our current findings.
Conclusions
In summary, the expression profiles of the primary lung
cancer, adjacent benign lung tissue, and metastatic brain
tissue from one patient were established using an RNA-Seq
assay, and subsequent bioinformatic analyses demonstrated
that the actinin gene ACTN4 and the pathways involved in
the regulation of cytoskeleton organization, cell motility,
and focal adhesion are indispensable for the process of lung
cancer metastasis to the brain. ACTN4 contributes to the
brain metastasis of lung cancer mainly through regulating
actin cytoskeleton organization, cell motility, and focal
adhesion.
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